12/17/15 - 02:16 PM EST
The charges brought against Martin Shkreli are not related at all to the drug-price gouging which made him a public villain and the target of politicians like Hillary Clinton.
12/17/15 - 08:48 AM EST
AstraZeneca and Gilead Sciences announced separate deals Thursday that strengthen their respective cancer and inflammatory disease pipelines.
12/15/15 - 08:14 AM EST
One of these biopharma executives, or the grouped nominees, will win the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO. Here are the best biopharma CEOs.
12/14/15 - 07:01 AM EST
Mitsubishi will pay Akebia $40 million upfront to license vadadustat for the Asian market. The Japanese drug maker will also contribute another $60 million towards Akebia'a global phase III program.
12/07/15 - 06:27 AM EST
Bluebird Bio is going to have a rough Monday because of the disappointing gene therapy data presented over the weekend at the American Society of Hematology annual meeting.
12/06/15 - 09:36 AM EST
Expanded results from a Global Blood study continue to show encouraging reductions in the number of sickled red blood cells, supported by other improvements in measures of the disease.
12/06/15 - 09:01 AM EST
Bluebird's challenge is to understand why exemplary results seen in a single French sickle cell patient are not being duplicated in the three other sickle cell patients treated more recently.
12/05/15 - 01:09 PM EST
Modified donor T cells and a molecular "safety switch" developed by Bellicum Pharmaceuticals improved the safety and outcome of stem cell transplants performed on children suffering from rare blood diseases.
12/05/15 - 10:39 AM EST
U.S. researchers using a personalized therapy made from genetically engineered T cells induced remissions in some patients with highly advanced multiple myeloma, a type of blood cancer affecting plasma cells.
12/02/15 - 01:43 PM EST
Zafgen shares plunge on concerns regulators could step in to halt clinical development of the company's obesity drug for patient-safety reasons.